Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Top Cited Papers
Open Access
- 12 October 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 306 (14), 1557-1565
- https://doi.org/10.1001/jama.2011.1456
Abstract
Increased surveillance of BRCA1/2 germ line mutation carriers is a generally accepted strategy for detecting early ovarian cancer. Women with BRCA1 mutations have a 39% to 54% cumulative lifetime risk of developing ovarian cancer and women with BRCA2 mutations have an 11% to 23% risk.1-3Keywords
This publication has 35 references indexed in Scilit:
- BRCA1 participates in DNA decatenationNature Structural & Molecular Biology, 2005
- BRCA1-Dependent Ubiquitination of γ-Tubulin Regulates Centrosome NumberMolecular and Cellular Biology, 2004
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003
- Cancer Risks in BRCA2 Mutation CarriersJNCI Journal of the National Cancer Institute, 1999
- Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.1999
- Frequency of germline and somatic BRCA1 mutations in ovarian cancer.1998
- Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.Journal of Clinical Oncology, 1998
- Involvement of Brca2 in DNA RepairMolecular Cell, 1998
- Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.1998
- Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1New England Journal of Medicine, 1996